Article Text

PDF
AB0511 Discontinuation of Methotrexate Treatment in Patients with Rheumatoid Arthritis and Relatiomships with Candidate Single Nucleotide Polymorphisms
  1. T. Soukup1,
  2. M. Dosedel2,
  3. P. Pavek3,
  4. J. Nekvindova4,
  5. A.A. Kubena2,
  6. I. Barvik5,
  7. J. Vlcek6,
  8. P. Bradna1
  1. 12nd Department of Internal Medicine-Gastroenterology, Charles University in Prague, Medical Faculty and University Hospital in Hradec Kralove
  2. 2Department of Social and Clinical Pharmacy
  3. 3Department of Pharmacology and Toxicology, Charles University in Prague, Faculty of Pharmacy in Hradec Kralove
  4. 4Institute of Clinical Biochemistry and Diagnostics, Charles University in Prague, University Hospital in Hradec Kralove
  5. 5Institute of Physics, 5Charles University in Prague, Faculty of Mathematics and Physics
  6. 6Department of Social and Clinical Pharmacy, Charles University in Prague, University Hospital in Hradec Kralove, Hradec Králové, Czech Republic

Abstract

Background Some single nucleotide polymorphisms (SNPs) might be predictive of methotrexate (MTX) therapeutic outcome in rheumatoid arthritis (RA).

Objectives The aim of this study was to determine whether SNPs in key MTX pathway genes might be predictive of an adverse drug reactions (ADR) and MTX discontinuation in RA patients treated with peroral MTX.

Methods There were 185 patients enrolled in the retrospective study, all of whom fulfilled the 1987 RA criteria of the American College of Rheumatology. The patients were currently or previously treated with peroral MTX. Genotyping was performed by quantitative PCR with allelic discrimination using commercial TaqMan (allele-specific) assays (Life Technologies, USA): (ADORA2A, rs2298383), (ADORA2A, rs3761422), (ADORA2A, rs2267076), (ADORA2A, rs2236624), (AMPD1, rs17602729), (ATIC, rs2372536), (ITPA, rs1127354), (MTHFD1, rs2236225), (MTHFR, rs1801131), (MTHFR, rs1801133), (SLC01B1, rs4149056).

Results Clinical data were available in 185 patients: mean age 58.7 years, SD ±12.17, age of 29-85 years. 30.3% of patients were male. MTX treatment was discontinued in 33 (17.8%) patients owing to ADR (hepatopathy, n=12; infection, n=10; dyspepsia, n=9; leucopenia, n=1; alopecia, n=1). 83 patients were treated by MTX monotherapy or MTX together with glucocorticoids. Other patients were treated by MTX in a combination with conventional synthetic or biologic DMARDs. Presence and absence of ADR were evaluated in relation to the identified genotypes. We revealed no evidence to support association of the presence of ADR and the following SNPs: ATIC rs2372536, AMPD1 rs17602729, ITPA rs1127354, SNPs of ADORA2A (rs2298383, rs3761422, rs2267076, and rs2236624), MTHFD1 rs2236225, MTHFR rs1801131, MTHFR rs1801133 and SLC01B1 rs4149056. Stratification of different ADRs in ITPA 94CC and ITPA 94CA genotypes showed association with dyspepsia P=0.01 using Kendall's test, in case of MTX DMARDs monotherapy P=0.046 respectively. ITPA 94AA genotype have not been found.

Conclusions In conclusion, we found for the first time that ITPA 94CC genotype is associated with a higher risk of dyspepsia in Caucasian RA patients treated with peroral MTX.

Acknowledgements This work was supported by a research project MH CZ - DRO (UHHK, 00179906) to T.S. and supported by research project PRVOUK P37-08 (from Charles University).

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.